Hudson Bay Capital Management’s Climb Bio CLYM Stock Holding History

Hudson Bay Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-54,460	Closed	-$373K	–	1755
2026 Q1	$373K	Buy	54,460 +5,724	+12%	+$33K	﹤0.01%	1010
2025 Q4	$195K	Buy	+48,736	New	+$117K	﹤0.01%	975
2022 Q2	–	Sell	-100,000	Closed	-$839K	–	1432
2022 Q1	$839K	Hold	100,000	–	–	0.01%	844
2021 Q4	$1.05M	Hold	100,000	–	–	0.01%	786
2021 Q3	$1.8M	Buy	+100,000	New	+$2.07M	0.02%	655

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Hudson Bay Capital Management's CLYM Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 54,460 shares — an estimated $373K sold.

Hudson Bay Capital Management first reported a position in CLYM in Q3 2021 and held it in 5 quarters. The position peaked at $1.8M in Q3 2021. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Hudson Bay Capital Management reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
Hudson Bay Capital Management sold 54,460 Climb Bio shares in Q2 2026, an estimated $373K.
Hudson Bay Capital Management first reported a position in Climb Bio in Q3 2021 and held it in 5 quarters.
Hudson Bay Capital Management's Climb Bio position peaked at $1.8M in Q3 2021.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.